Targeting PRKCN, an Essential Driver Orchestrating mTOR-IRF4 Axis Independently of Kinase Activity, in Multiple Myeloma.

Multiple myeloma (MM) remains incurable, necessitating development of novel therapeutic targets. Deregulated PRKCN is implicated in solid tumors, while its role in MM remains elusive. Here, PRKCN is identified as a super-enhancer-driven gene associated with adverse prognosis in MM. PRKCN is transactivated by NF-κB signaling intrinsically existing or exogenously provoked. Constitutive or inducible knockdown of PRKCN significantly impairs cell growth and tumorigenicity, while overcoming drug resistance. PRKCN harnesses IRF4 to exert its effect, and in turn, IRF4 directly induces PRKCN transcription, establishing a feed-forward IRF4-PRKCN circuit. Furthermore, PRKCN fosters IRF4 expression by activating mTORC1/C2 signaling pathways via physical interaction with mTOR. Surprisingly, PRKCN modulates mTOR-IRF4 axis and cell growth independently of its acknowledged kinase activity yet requiring activation loop phosphorylation. Intriguingly, PRKCN silencing evokes interferon signaling and confers increased sensitivity to interferon. Finally, targeting PRKCN with an orally bioavailable inhibitor suppresses MM cell growth and overcomes drug resistance in vitro, and elicits robust efficacy in cell line-derived xenografts and a patient-derived xenograft, which is connected with the mitigated PRKCN expression and activation loop phosphorylation as well as blunted mTOR-IRF4 axis. Collectively, our study delineates PRKCN function that links aberrant NF-κB signaling and mTOR-IRF4 axis, supporting clinically targeting PRKCN in MM.

• Publication year

  2026

• Venue

  Advancement of science

• Publication date

  2026-02-08

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/advs.202518975PMID 41655233
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Loss of BCL7A Permits IRF4 Transcriptional Activity and Cellular Growth in Multiple Myeloma.

  2025cited by this paper
• DOT1L inhibition reprograms innate immunity to potentiate immunomodulatory drug responses in multiple myeloma.

  2025cited by this paper
• Macrophage-derived pro-inflammatory cytokines augment the cytotoxicity of cytokine-induced killer cells by strengthening the NKG2D pathway in multiple myeloma

  2025cited by this paper
• Super enhancer acquisition drives expression of oncogenic PPP1R15B that regulates protein homeostasis in multiple myeloma

  2024cited by this paper
• IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma.

  2024cited by this paper
• C-terminal binding protein 2 is a novel tumor suppressor targeting the MYC-IRF4 axis in multiple myeloma

  2024cited by this paper
• Targeting mTOR signaling pathways in multiple myeloma: biology and implication for therapy

  2024cited by this paper
• The ADAR1-regulated cytoplasmic dsRNA-sensing pathway is a novel mechanism of lenalidomide resistance in multiple myeloma

  2024cited by this paper
• Targeted interferon therapy with modakafusp alfa for relapsed or refractory multiple myeloma

  2024cited by this paper
• Chimeric antigen receptor T cells targeting FcRH5 provide robust tumour-specific responses in murine xenograft models of multiple myeloma

  2023cited by this paper
• Super-enhancers include classical enhancers and facilitators to fully activate gene expression

  2023cited by this paper
• Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma

  2023cited by this paper
• Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group.

  2023cited by this paper
• Protein kinase D2 and 3 promote prostate cancer cell bone metastasis by positively regulating Runx2 in a MEK/ERK1/2-dependent manner.

  2023cited by this paper
• Small Molecule Inhibitors of Protein Kinase D: Early Development, Current Approaches, and Future Directions.

  2022cited by this paper
• The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma

  2022cited by this paper
• Myeloma-specific superenhancers affect genes of biological and clinical relevance in myeloma

  2021cited by this paper
• Super Enhancer-Mediated Upregulation of HJURP Promotes Growth and Survival of t(4;14)-Positive Multiple Myeloma

  2021cited by this paper
• Oncogenic RAS commandeers amino acid sensing machinery to aberrantly activate mTORC1 in multiple myeloma

  2021cited by this paper
• TRIM47 activates NF-κB signaling via PKC-ε/PKD3 stabilization and contributes to endocrine therapy resistance in breast cancer

  2021cited by this paper
• A phosphoproteomic approach reveals that PKD3 controls PKA-mediated glucose and tyrosine metabolism

  2021cited by this paper
• Developments in the Discovery and Design of Protein Kinase D Inhibitors

  2021cited by this paper
• Inhibition Lysosomal Degradation of Clusterin by Protein Kinase D3 Promotes Triple‐Negative Breast Cancer Tumor Growth

  2021cited by this paper
• Multiple myeloma

  2021cited by this paper
• Protein Kinase D3 promotes the cell proliferation by activating the ERK1/c‐MYC axis in breast cancer

  2020cited by this paper
• T cells redirected against Igβ for the immunotherapy of B cell lymphoma

  2019cited by this paper
• The kinase PKD3 provides negative feedback on cholesterol and triglyceride synthesis by suppressing insulin signaling

  2019cited by this paper
• Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4

  2019cited by this paper
• SMAD4 promotes TGF-&bgr;–independent NK cell homeostasis and maturation and antitumor immunity

  2018cited by this paper
• IMiDs prime myeloma cells for daratumumab-mediated cytotoxicity through loss of Ikaros and Aiolos.

  2018cited by this paper
• Metformin induces autophagy and G0/G1 phase cell cycle arrest in myeloma by targeting the AMPK/mTORC1 and mTORC2 pathways

  2018cited by this paper
• KDM6B modulates MAPK pathway mediating multiple myeloma cell growth and survival

  2017cited by this paper
• CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL.

  2015cited by this paper
• The KDM3A–KLF2–IRF4 axis maintains myeloma cell survival

  2015cited by this paper
• SENP1 inhibition induces apoptosis and growth arrest of multiple myeloma cells through modulation of NF-κB signaling.

  2015cited by this paper
• Gene Expression Profiling Identifies IRF4-Associated Molecular Signatures in Hematological Malignancies

  2014cited by this paper
• Selective inhibition of tumor oncogenes by disruption of super-enhancers.

  2013cited by this paper
• PKD2 and PKD3 promote prostate cancer cell invasion by modulating NF-&kgr;B- and HDAC1-mediated expression and activation of uPA

  2012cited by this paper
• Protein kinase D3 sensitizes RAF inhibitor RAF265 in melanoma cells by preventing reactivation of MAPK signaling.

  2011cited by this paper
• Classical and/or alternative NF-kappaB pathway activation in multiple myeloma.

  2010cited by this paper
• IRF4 addiction in multiple myeloma

  2008cited by this paper
• Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma.

  2007cited by this paper
• The Nuclear Import of Protein Kinase D3 Requires Its Catalytic Activity*

  2006cited by this paper
• Requirement of Protein Kinase D Tyrosine Phosphorylation for VEGF-A165-induced Angiogenesis through Its Interaction and Regulation of Phospholipase Cγ Phosphorylation*

  2006cited by this paper
• NF‐kB inhibition as a strategy to enhance etoposide‐induced apoptosis in K562 cell line

  2006cited by this paper
• Individual C1 domains of PKD3 in phorbol ester-induced plasma membrane translocation of PKD3 in intact cells.

  2005cited by this paper
• Protein kinase D regulates basolateral membrane protein exit from trans-Golgi network

  2004cited by this paper
• Regulation of protein kinase Cnu by the B-cell antigen receptor.

  2003cited by this paper
• Expression of myc‐family genes in established human multiple myeloma cell lines: L‐myc but not c‐myc gene expression in the U‐266 myeloma cell line

  1992cited by this paper

• No citing papers are available for this paper.